Petrelintide (5mg/10mg)
Long-Acting Amylin Analog — The Non-Incretin Path
Petrelintide is listed for amylin-pathway research. Catalog vial contents are 5mg / 10mg; select the required strength before ordering. This material is supplied for Research Use Only, not as a medicine or a product for human or veterinary use.
Research Applications & Benefits
- Long-acting amylin receptor agonist
- Once-weekly subcutaneous dosing
- Mechanism distinct from GLP-1 / GIP
- Potential incretin-class GI-tolerability alternative
What is Petrelintide?
Zealand Pharma's long-acting amylin analog engineered for once-weekly dosing — pursuing satiety and glycemic control through a non-incretin mechanism distinct from GLP-1 / GIP agonists.
Listed vial contents: 5mg / 10mg. These are supplied quantities, not administration doses. Current pricing and availability are shown in the strength selector.
What mechanisms are being studied?
Petrelintide is a long-acting analog of human amylin (the pancreatic beta-cell co-hormone secreted with insulin). It activates amylin and calcitonin receptors in the brainstem area postrema, producing satiety, slowed gastric emptying, and post-prandial glucagon suppression. Because amylin signaling is mechanistically distinct from GLP-1 / GIP, petrelintide is studied as a non-incretin satiety pathway and as a combination partner for incretin agonists.
What are the research questions?
- Obesity research: Phase 2 monotherapy reported ~8.6% mean weight loss at 16 weeks across dose arms.
- Combination research: Studied alongside semaglutide and other GLP-1 agonists, testing whether amylin + GLP-1 (analogous to cagrilintide + semaglutide / CagriSema) improves efficacy and tolerability.
- GI-tolerability comparator: Used in studies investigating whether non-incretin satiety pathways produce less nausea / vomiting at equivalent weight-loss magnitudes.
- Glycemic-control research: Beta-cell-derived signaling mechanism gives a complementary glucose-regulation profile to incretin agonists.
What does the published work describe?
Zealand Pharma Phase 1b (2024) — dose-dependent weight loss over 16 weeks with favorable GI tolerability. Zealand / Boehringer Ingelheim Phase 2 ZUPREME-1 (2025) — ~8.6% mean weight loss at 16 weeks. Phase 3 program planned for 2026.
What are the limits of this evidence?
The research described concerns the cited experimental materials and models, not proof that this supplied vial is a treatment. Cell or animal findings do not establish human benefits. Clinical findings, where cited, apply to the tested formulation and population; they do not validate this research product for human use.
Study references
- Zealand Pharma Petrelintide Phase 1b disclosure, 2024
- Zealand / Boehringer Ingelheim Phase 2 ZUPREME-1 disclosure, 2025
- Lutz TA. Physiol Behav 2010 — amylin pharmacology
These are the catalog's existing bibliographic references. No new source verification is implied by this presentation.
How should I check lot documentation?
Match the product, strength and lot to an original analysis document. Literature describes experimental findings; it does not verify the contents of this inventory. A report is evidence only for the product, strength and lot it names.
How is Petrelintide handled in the lab?
For Petrelintide, record the product code PETR-5, selected strength and lot before opening. Follow the material-specific safety data sheet and laboratory SOP, with appropriate gloves, eye protection and containment. For a documented dry preparation, let the sealed vial equilibrate before opening to reduce condensation; minimize time open and use clean, compatible vessels.
Choose a solvent for Petrelintide from the documented sequence or chemical identity, salt form and assay requirements. Test a small portion first and record pH, solvent composition and clarity. Do not assume one diluent works for every research material; include a solvent-only control and establish compatibility before using the stock in an assay. For a documented lipid-modified construct, evaluate aggregation and adsorption as well as apparent solubility; check compatibility again after dilution into the final assay buffer.
For Petrelintide, calculate mass concentration as measured material mass divided by final solution volume. Calculate molarity only with a documented molecular weight for the supplied chemical form; the catalog lists ~4200 g/mol as a reference, not lot confirmation. Where available, use matched-lot net content rather than treating chromatographic purity as a mass correction. Record both stock concentration and subsequent dilution factors.
Use the documented storage conditions for the supplied Petrelintide form and lot. For a documented lyophilized preparation, keep the vial sealed and protected from moisture; for solutions, validate temperature, light exposure and holding time in the assay. Use compatible single-use aliquots when appropriate to reduce repeated freeze-thaw. No universal temperature or 28-day solution shelf life is established by the catalog name.
A Petrelintide laboratory protocol should record identity, product code PETR-5, strength, lot, applicable analysis results, solvent and pH, stock concentration, dilution sequence, vessel type, storage history and assay endpoints. Include vehicle and reference controls, independent replicates and predefined acceptance criteria. Separate handling validation from biological interpretation; these notes do not provide administration or dosing instructions.
Research Use Only. Not for human consumption, therapeutic, veterinary or any in-vivo use.
Product Specifications
- Compound
- Petrelintide
- CAS Number
- 2748279-04-7
- Molecular Weight
- ~4200 g/mol
- HPLC Purity Specification
- ≥99%
- Category
- GLP-1 & Metabolic
- Starting Price
- $189.00 USD
- Country of Origin
- United States
- Shipping
- Cold-chain insulated packaging, fast domestic delivery
- Payment
- Card, ACH, and cryptocurrency (10% discount)
Quality & Verification
Petrelintide has a catalog purity specification of ≥99%; this is not a measured result for every vial. Match the product, exact strength, batch and lot to its analysis record and read only the reported fields. HPLC peak-area purity, measured content and endotoxin are separate measurements. A blank field means no result is reported, not zero or passed. A purity percentage alone does not establish identity, sterility or suitability for human use.
Frequently Asked Questions
What is Petrelintide?
Petrelintide is listed for amylin-pathway research. Catalog vial contents are 5mg / 10mg; select the required strength before ordering. This material is supplied for Research Use Only, not as a medicine or a product for human or veterinary use.
What strengths of Petrelintide are available?
The catalog lists 5mg / 10mg. These labels describe vial contents, not administration doses. Select the required strength for current pricing and availability; match analysis records to that exact strength and lot.
How should I interpret Petrelintide purity results?
Petrelintide has a catalog purity specification of ≥99%; this is not a measured result for every vial. Match the product, exact strength, batch and lot to its analysis record and read only the reported fields. HPLC peak-area purity, measured content and endotoxin are separate measurements. A blank field means no result is reported, not zero or passed. A purity percentage alone does not establish identity, sterility or suitability for human use.
How should Petrelintide be handled in the laboratory?
For Petrelintide, record the product code PETR-5, selected strength and lot before opening. Follow the material-specific safety data sheet and laboratory SOP, with appropriate gloves, eye protection and containment. For a documented dry preparation, let the sealed vial equilibrate before opening to reduce condensation; minimize time open and use clean, compatible vessels.
How do I choose a laboratory solvent for Petrelintide?
Choose a solvent for Petrelintide from the documented sequence or chemical identity, salt form and assay requirements. Test a small portion first and record pH, solvent composition and clarity. Do not assume one diluent works for every research material; include a solvent-only control and establish compatibility before using the stock in an assay. For a documented lipid-modified construct, evaluate aggregation and adsorption as well as apparent solubility; check compatibility again after dilution into the final assay buffer.
How do I calculate a Petrelintide stock concentration?
For Petrelintide, calculate mass concentration as measured material mass divided by final solution volume. Calculate molarity only with a documented molecular weight for the supplied chemical form; the catalog lists ~4200 g/mol as a reference, not lot confirmation. Where available, use matched-lot net content rather than treating chromatographic purity as a mass correction. Record both stock concentration and subsequent dilution factors.
How should Petrelintide be stored after preparation?
Use the documented storage conditions for the supplied Petrelintide form and lot. For a documented lyophilized preparation, keep the vial sealed and protected from moisture; for solutions, validate temperature, light exposure and holding time in the assay. Use compatible single-use aliquots when appropriate to reduce repeated freeze-thaw. No universal temperature or 28-day solution shelf life is established by the catalog name.
What should a Petrelintide lab protocol document?
A Petrelintide laboratory protocol should record identity, product code PETR-5, strength, lot, applicable analysis results, solvent and pH, stock concentration, dilution sequence, vessel type, storage history and assay endpoints. Include vehicle and reference controls, independent replicates and predefined acceptance criteria. Separate handling validation from biological interpretation; these notes do not provide administration or dosing instructions.
Does Fmoc or Boc synthesis explain this Petrelintide product?
Fmoc and Boc are peptide protecting-group strategies, not proof of how this Petrelintide lot was made. For sequence-defined peptides, synthesis review can examine deletion products, incomplete deprotection and modifications using the method and matching analytical evidence. A single chromatographic peak does not by itself establish sequence.
Is Petrelintide for human use?
No. Petrelintide is strictly Research Use Only. It is not intended for human or veterinary use, diagnosis or treatment. Laboratory handling guidance is not an administration protocol.
Research Use Only. This product is intended for licensed laboratory research and is not for human or veterinary use.
